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Doxorubicin-loaded micelles were prepared from a copolymer comprising cholic acid (CA) and polyethyleneimine
(PEI) for the delivery of antitumor drugs. The CA-PEI copolymer was synthesized via pairing mediated by
N,N’-dicyclohexylcarbodiimide and N-hydroxysuccinimide using dichloromethane as a solvent. Fourier transform
infrared and nuclear magnetic resonance analyses were performed to verify the formation of an amide linkage
between CA and PEI and doxorubicin localization into the copolymer. Dynamic light scattering and transmission
electron microscopy studies revealed that the copolymer could self-assemble into micelles with a spherical
morphology and an average diameter of <200 nm. The CA-PEI copolymer was also characterized by X-ray
diffraction and differential scanning calorimetry. Doxorubicin-loaded micelles were prepared by dialysis method. A
drug release study showed reduced drug release with escalating drug content. In a cytotoxicity assay using human
colorectal adenocarcinoma (DLD-1) cells, the doxorubicin-loaded CA-PEI micelles exhibited better antitumor activity
than that shown by doxorubicin. This is the first study on CA-PEI micelles as doxorubicin carriers, and this study
demonstrated that they are promising candidates as carriers for sustained targeted antitumor drug delivery system.
Keywords: Micelles, Nanoparticles, Cholic acid, Polyethyleneimine, DoxorubicinBackground
Several therapeutic anticancer drugs, although pharmaco-
logically effective in cancer treatment, are restricted in their
clinical applications because of their severe toxicity [1]. The
severe toxicity is usually due to the lipid solubility of most
of the anticancer drugs (>70%) and the therapeutic doses
that are often very high [2]. Doxorubicin is one of the most
successful drugs for targeting a broad range of cancers.
Nevertheless, its clinical use is hindered by its side effects,
which include cardiotoxicity and acquired drug resistance.
To overcome these complications, researchers have placed
an emphasis on developing nanoscale anticancer drug car-
riers for improving therapeutic efficacy in addition to redu-
cing unwanted side effects [3].* Correspondence: mciamin@pharmacy.ukm.my
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in any medium, provided the original work is pPolymeric micelles self-assembled from amphiphilic
copolymers have gained much interest for use in targeted
anticancer drug delivery since they have a number of
physico- and bio-chemical advantages over other types of
nanocarriers. Polymeric micelles are virus-sized with a
core-shell structure having a hydrophobic core and a
hydrophilic shell and, more significantly, inherent stealth.
Polymeric micelles seem ideal for the targeted and con-
trolled delivery of hydrophobic anticancer drugs, including
paclitaxel and doxorubicin [4], in that they significantly in-
crease their water solubility, extend their circulation time,
passively target tumor tissues [5], increase their bioavail-
ability, have tremendous biocompatibility, and are degrad-
able in vivo into nontoxic products. Several types of
polymer blocks can be used to form micelles, of which the
most studied include poly(α-hydroxy esters) [6] (such as
polylactide [7], polyglycolide [8], and poly(ε-caprolactone)
[9]), polyether [10], hydrotrophic polymers [11], and poly
(amino acids) [12]. Several attempts have been made ton Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
Figure 1 Schematic representation of carbodiimide-mediated
coupling of CA-PEI.
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combinations to achieve ideal drug delivery in vitro as well
as in vivo.
Cholic acid (CA), a bile acid, is an amphiphilic steroid
molecule naturally synthesized from cholesterol, which
organizes into micelles above the critical micelle concen-
tration (CMC). Bile acids, together with the phospholi-
pids, vary the permeability of cell membranes [13]. Some
bile acids form hydrogen-bonded aggregates with some
drugs, which may lead to alterations in drug bioavailabil-
ity [14]. Polyethyleneimine (PEI) is a cationic synthetic
vector mainly used for gene delivery owing to its high
nucleic acid condensing potential, ability to escape
endosomes [15], nuclear localization capability [16],
and promising transfection efficacy both in vitro and
in vivo [15].
We synthesized doxorubicin-loaded cholic acid-
polyethyleneimine (CA-PEI) micelles as an antitu-
mor drug delivery system. The antitumor activity
of the doxorubicin-loaded CA-PEI micelles was




CA, PEI (average molecular weight (MW) approximately
1,300), N,N’-dicyclohexylcarbodiimide (DCC), N-hydro-
xysuccinimide (NHS), hydrochloric acid (HCl), triethyla-
mine, tetrahydrofuran, and dichloromethane were
purchased from Sigma-Aldrich (St. Louis, MO, USA).
Doxorubicin was purchased from Calbiochem (Merck
KGaA, Darmstadt, Germany). The Spectra/Por™ dialysis
membrane (MW cutoff (MWCO) = 1,000 g/mol) was
purchased from Spectrum Labs (Rancho Dominguez,
CA, USA).
Synthesis of the CA-PEI copolymer
The side-chain carboxyl group at the C-24 position in
CA was conjugated to the terminal amine group of PEI.
This was carried out by dissolving CA in tetrahydrofuran
and activating it with DCC and NHS at 25°C for 8 h. CA
was then precipitated in ice-cold n-hexane and dried in
an oven at 40°C for 2 h. The activated CA was then con-
jugated to the primary amine group of PEI by incubating
for 15 h in dichloromethane (Figure 1) using CA-PEI
molar ratios of 1:1, 1:2, 1:4, 3:1, and 4:1.
The resulting conjugates were dried using a rotary
evaporator and dissolved in dilute HCl followed by pre-
cipitation with cold acetone. Finally, they were dissolved
in deionized water, filtered, and freeze-dried.
Analysis of the conjugates
To assess their functional groups, drug-loaded and blank
conjugates were characterized using a Fourier trans-form infrared (FTIR) spectrophotometer (Spectrum 100,
PerkinElmer, Waltham, MA, USA) using the potassium
bromide (KBr) disc method. For each sample, 16 scans
were obtained at a resolution of 4 cm−1 in the range of
4,000 to 700 cm−1. Further characterization of the conju-
gates was also performed using nuclear magnetic reson-
ance (NMR) spectroscopy (Bruker Avance III, FT-NMR
600 MHz with cryoprobe, Germany). The CMCs of
the micelles were determined using the dynamic light
scattering method (Zetasizer Nano ZS, Malvern Instru-
ments, Malvern, Worcestershire, UK) at 37°C with a
scattering angle of 90°. The alterations in light intensity
were recorded, and a graph was plotted for the molar
concentrations of the samples versus the mean intensity.
A sharp increase in the intensity signified the formation
of micelles. Samples for morphological investigations
were prepared by air-drying a drop of the micellar sus-
pension on a carbon-coated formvar film on a 400-mesh
copper grid. The morphology of the micelles was then
visualized by transmission electron microscopy (TEM;
Tecnai™ Spirit, FEI, Eindhoven, The Netherlands) at
220 kV and under various magnifications. The conjugates
were observed under a light microscope (FluoView
FV1000, Olympus, Tokyo, Japan). The X-ray diffraction
(XRD) patterns of the CA-PEI conjugates were analyzed
with an X-ray diffractometer (D8 ADVANCE, Cu Kα =
1.54184 Å, Bruker, WI, USA). The thermal behavior of the
Figure 2 FTIR spectra and light microscope image. FTIR spectra of CA, PEI, doxorubicin, CA-PEI 3:1 blank micelles, and doxorubicin-loaded CA-
PEI 3:1 micelles (a). Light microscope image of CA-PEI 3:1 micelles (b).
Figure 3 1HNMR spectrum of CA-PEI copolymer at a molar feed ratio of 3:1.
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Figure 4 Critical micelle concentrations of CA-PEI micelles.
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rimetry (DSC) (Diamond DSC, PerkinElmer, Waltham,
MA, USA).
Preparation of the doxorubicin-loaded CA-PEI micelles
Doxorubicin hydrochloride (2.5 mg) was dissolved in 2 mL
chloroform and mixed with 2 μL of triethylamine. CA-PEI
copolymers of different molar ratios (1:1, 1:2, 1:4, 3:1, and
4:1) were dissolved in 2 mL methanol. The doxorubicin
and CA-PEI copolymer solutions were mixed in a glass vial
and kept in the dark for 24 h. The solution was then
poured drop by drop into deionized water (20 mL) under
ultrasonic agitation using a sonifier (Branson Ultrasonics
Co., Danbury, CT, USA) at a power level of 3 for 10 min.
The organic solvents namely chloroform and methanol
were then completely removed by vacuum distillation using
a rotary evaporator. The doxorubicin-loaded micelle solu-
tion was then dialyzed against 1 L of deionized water for
24 h at 20°C using a cellulose membrane bag (MWCO=
1,000) to remove unloaded doxorubicin. The deionized
water was substituted every 2 h for the first 12 h and thenFigure 5 TEM images of CA-PEI micelles. CA-PEI 3:1 (a, b), CA-PEI 1:1 (c,
bars represent 100 nm, and white scale bars represent 50 nm. The magnifi
(b, d, i), and × 87,000 (f, g).every 6 h. Immediately after this, the product was freeze-
dried. The extent of doxorubicin loaded into the micelles
was determined from a calibration curve of pure doxorubi-
cin. Freeze-dried doxorubicin-loaded micelles were dis-
solved in 4 mL of a DMSO and methanol mixture (1:1),
and the absorbance was measured at 480 nm using a UV-
1601 spectrophotometer (Shimadzu Corp., Kyoto, Japan).
The drug loading content (DLC) is defined as the ratio
of mass of the drug encapsulated within the micelles to
the total mass of drug-loaded micelles, while the entrap-
ment efficiency (EE) is the ratio of mass of drug loaded
into the micelles to the mass of drug initially added. The
DLC and EE were calculated according to the following
equations:
DLC wt:%ð Þ ¼ mass of drug encapsulated in micelles=
mass of drug loaded micelles 100
ð1Þ
EE %ð Þ ¼ mass of drug loaded in micelles=
mass of drug initially added 100 ð2Þd), CA-PEI 4:1 (e, f), CA-PEI 1:2 (g, h), and CA-PEI 1:4 (i, j). Black scale
cation of the images were × 160,000 (a, c), ×135,000 (e, h, j), ×105,000
Figure 6 XRD patterns of CA and CA-PEI conjugates of five different molar feed ratios.
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The drug release experiment was carried out in vitro. A
doxorubicin-loaded micelle solution previously prepared
by dialysis was used for release analysis. This solution
was introduced into the dialysis membrane. Subse-
quently, the dialysis membrane was placed in a 200-mL
beaker with 100 mL of phosphate-buffered saline (PBS).
This beaker was placed on a magnetic stirrer with a stir-
ring speed of 100 rpm at 37°C. At suitable intervals,
3 mL samples were taken from the release medium and
an equivalent volume of fresh medium was added. TheFigure 7 DSC curves of CA, PEI, and CA-PEI conjugates with five diffeconcentration of doxorubicin in each sample was mea-
sured by ultraviolet–visible spectrophotometry at 480 nm.
Cytotoxicity analysis
Human colorectal adenocarcinoma (DLD-1) and Chinese
hamster lung fibroblast (V79) cell lines were obtained
from the American Type Culture Collection (Manassas,
VA, USA). DLD-1 cells were cultured and maintained in
Roswell Park Memorial Institute-1640 (RPMI-1640)
medium, whereas V79 cells were cultured in Dulbecco’s
modified Eagle’s medium (DMEM). Both cell lines wererent molar feed ratios.
Table 1 DLC and EE of doxorubicin-loaded micelles
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streptomycin and maintained at 37°C in a humidified 5%
CO2/95% air atmosphere.
The impact of the blank micelles on cell viability was
assessed using V79 cells. Cultured cells maintained in
DMEM were seeded in 96-well culture plates at 4 × 104
cells per well and incubated for 24 h. The cells were
then treated with increasing concentrations of blank
micelles ranging from 31.25 to 500 μg · mL−1 and incu-
bated for an additional 24 h at 37°C in a 5% CO2/95%
air atmosphere. Next, 20 μL of Alamar BlueW (Invitro-
gen, Carlsbad, CA, USA) was introduced to every well,
and the cells were incubated for a further 4 h. The ab-
sorbance of each sample was measured at 570 nm with a
microplate reader (Varioskan Flash, Thermo Scientific,
Waltham, MA, USA). Cell viability was determined
using the following equation:
Cell viability %ð Þ ¼ A570of treated cells=A570of control cells 100
ð3Þ
The cytotoxicity of the doxorubicin-loaded micelles
was determined using the Alamar blue assay. DLD-1
cells were seeded in 96-well culture plates at 2 × 104 cells
per well and incubated for 48 h at 37°C in 5% CO2/95%
air atmosphere. After the medium was removed, the
cells were treated with 200 μL of 50, 25, 12.5, 6.25, 1.56,
0.19, and 0.09 μg · mL−1 of free doxorubicin andFigure 8 Doxorubicin release from CA-PEI micelles at pH 7.4.doxorubicin-loaded micelles, respectively. After 24-h in-
cubation, Alamar blue solution was added to each well,
and the incubation was continued for 4 h. The absorb-
ance of each sample at 570 nm (A570) was measured
with a microplate reader. Cell viability was determined
using the following equation:
Percentage inhibition %ð Þ ¼ 100 cell viability %ð Þ
ð4Þ
Results and discussion
Formation and characterization of the CA-PEI micelles
The facially amphipathic CA was introduced into PEI to
prepare stable CA-PEI micelles as carriers for the deliv-
ery of doxorubicin. The CA terminal carboxyl group that
was principally activated using DCC/NHS chemistry was
conjugated to the PEI amine group via an amide linkage
to obtain the CA-PEI conjugate (Figure 1).
The FTIR spectra of the conjugates were somewhat
consistent between the molar ratios tested (1:1, 1:2, 1:4,
3:1, and 4:1) (Figure 2a). In the CA-PEI spectra, peaks
for the N-H bending, C =O absorbance band, and C-H
and N-H stretching were observed at 1,590, 1,630, 2,850
to 2,930, and 3,300 cm−1, respectively. The overlapping
of the C =O absorbance band (1,630 cm−1) with the
N-H bending band (1,590 cm−1) appeared as a doublet
in the CA-PEI spectra. This indicated the formation of
an amide linkage between CA and PEI [17]. The spectra
of the doxorubicin-loaded micelles indicated the absence
of the characteristic peaks for doxorubicin, showing that
the drug was contained within the hydrophobic micelle
core [18].
The freeze-drying process produced white crystalline
CA-PEI conjugates where their morphology was observed
under the light microscope as shown in Figure 2b. The
synthesized conjugates appeared as slender, needle-shaped
Figure 9 Cytotoxicity of doxorubicin-loaded micelles on DLD-1
cells after 24 h. Twenty thousand cells were exposed to
doxorubicin and doxorubicin-incorporated CA-PEI micelles for 24 h.
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and the length of the units varied slightly.
In the hydrogen nuclear magnetic resonance (1HNMR)
spectra (Figure 3), proton shifts were observed in the re-
gion of 1 to 2 ppm, which are the characteristic peaks of
CA. These are the doublet, triplet, and multiplet peaks
indicating the structure of CA. Integration values in the
region of 1 to 2 ppm designate the number of protons in
CA. Proton shifts from 2.6 to 3.52 ppm indicated the
presence of PEI. At 4.5 ppm, there was a proton shift of
the solvent.
The CMCs of a series of CA-PEI solutions of different
molar ratios are shown in Figure 4. Changes in the lightFigure 10 Cell viability (%) of V79 cells at 24 h post-incubation with iintensity are symbolized as a function of the molar con-
centration, in which an abrupt increase designates the
formation of stable micelles. The results showed that the
micelles at 3:1 ratio had a lower CMC than those at
other ratios. Given that CA has a hydrophobic steroidal
nucleus, an increase in CA units could add to the hydro-
phobic interactions between the polymer chains in the
micelle core and stabilize the structure. This is signifi-
cant for the drug solubilization and EE of micelles
[19,20]. However, the CA-PEI micelles were ideally
stable merely up to a definite concentration of CA (3:1).
When the molar fraction of CA was raised further, it also
increased the hydrophilic segments, which raised the like-
lihood of interaction between the hydrophilic and hydro-
phobic segments and a decreased hydrophobicity of the
core, consequently leading to an increased CMC.
High CMCs are a key problem linked to micelle for-
mulations given intravenously or diluted in blood. Low
CMCs of CA-PEI micelles would thus offer some bene-
fits, such as stability against dissociation and precipita-
tion in blood due to dilution. In addition, embolism
caused by the elevated amount of polymers used for the
micelle formation could be avoided [21].
TEM micrographs of the CA-PEI micelles are shown
in Figure 5. The micelles were observed to have a spher-
ical shape and were uniform in size ranging from 150 to
200 nm. The bright areas perhaps encompassed the
hydrophobic part forming the micellar core, whereas the
hydrophilic corona appeared to be darker because this
region has a higher electron density than the core [22].
The formation of small, lustrous CA-PEI conjugates (1
to 2 mm) was an interesting finding; hence, they were
subjected to XRD analysis (Figure 6). For CA alone,
characteristic peaks were observed at 2θ = 12.0°, 13.1°,
and 19.8° [23]. In contrast, the XRD patterns of the CA-ncreasing concentrations of CA-PEI blank micelles.
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lattice peaks at 2θ = 7.6°, 15°, and 23.2°. The intensity of
the peak at 2θ = 7.6° was maximum for all CA-PEI con-
jugates. The sharp, intense, and broad peaks of the CA-
PEI conjugates indicated a crystalline nature of the
conjugate.
The conjugates were then subjected to DSC analysis
(Figure 7). When heated from 30°C to 250°C at 20°C/
min, the CA crystals exhibited endothermic peaks due
to fusion at 202°C [24], while a broad endothermic peak
of a relatively lesser intensity was observed for PEI at
220°C. The DSC curve of the CA-PEI conjugate had two
fusion peaks derived from CA and PEI at 220°C and
235°C, indicating the formation of conjugates. The in-
tensity of the first peak was slightly higher than that of
the second peak.
DLC and EE of micelles as calculated using Equations
1 and 2 are represented in Table 1. The in vitro release
profile of the doxorubicin-loaded micelles in PBS solu-
tion (pH 7.4) was obtained, which is summarized in
Figure 8. The drug release decreased as the drug content
increased in the micelles. Micelles with a molar ratio
(CA-PEI) of 1:4 had the maximum doxorubicin release
after 6 days. The micelles exhibited a sustained release
pattern of doxorubicin, which was characterized by an
initial burst release followed by a slow and continuous
drug release. In fact, this is a frequent observation for
doxorubicin release reported by a number of researchers
[25-29]. Doxorubicin is recognized to form a dimer in
aqueous media due to the chemical reaction between
the 30-NH2 group and the C9 α-ketol side chain. Given
that the doxorubicin dimer is almost water insoluble and
that its azomethine bond may readily be cleaved to re-
store the doxorubicin monomer, the later stage of sus-
tained drug release may involve regenerated doxorubicin
in addition to the doxorubicin dimer itself [30].
In vitro cell cytotoxicity
As shown in Figure 9, the percent inhibition of cancer
cells by the doxorubicin-loaded micelles improved from
the 1:4 to the 4:1 combinations. Incorporation of doxo-
rubicin into the CA-PEI micelles increased its cytotox-
icity toward cancer cells. The half-maximal inhibitory
concentration (IC50) values for the doxorubicin-loaded
micelles were lower than those for free doxorubicin. The
lower percentage inhibition and superior IC50 of doxo-
rubicin compared with those of the doxorubicin-loaded
micelles may well be accredited to the formation of
aggregates, which deter drug entry into the cells. In
addition, doxorubicin could be removed from tumor sites
by drug efflux pumps [31]. In contrast, the enhanced cyto-
toxicity of the doxorubicin-loaded micelles could be
explained by the higher permeability and retention of
micelles in tumor cells. In addition, increased penetrationof the doxorubicin-loaded micelles makes it possible for
the drug to be delivered to the site of action, which is
located in the nucleus, and therefore gives more time for
doxorubicin to interact with its substrate. The increased
cytotoxicity observed toward cancer cells could be linked
to an increased production of reactive oxygen species and
enhanced apoptosis. The ability of CA to modulate the
number of aberrant crypt foci by restraining their develop-
ment and growth and by eliminating a selected population
may also contribute to the cytotoxicity of the doxorubicin-
loaded micelles [32]. Both free doxorubicin and entrapped
doxorubicin caused cell death in a dose-dependent man-
ner. The cytotoxicity of doxorubicin is likely to increase
further in vivo due to the enhanced permeation and reten-
tion effects of the loaded micelles. These findings imply
that the selective uptake of micelles by cancer cells could
reduce the toxicity and adverse effects of doxorubicin. To
verify the low toxicity of blank micelles to normal cells,
cell viability was determined in V79 cells (Figure 10). The
blank micelles were not toxic to V79 cells in the tested
concentration ranges.Conclusions
Here, we report the synthesis of doxorubicin-loaded
novel CA-PEI micelles for the first time. The conjugates
readily formed micelles, which exhibited a uniform
spherical morphology as observed by TEM. XRD analysis
revealed that the conjugates had a crystalline structure.
Increasing the quantity of incorporated doxorubicin
decreased the release rate of the drug. Doxorubicin-loaded
CA-PEI micelles had an enhanced antitumor activity
against tumor cells in vitro compared with that of doxo-
rubicin itself. In contrast, when blank micelles were
exposed to normal (V79) cells, they did not exhibit consid-
erable toxicity. Together, these results indicate the poten-
tial of doxorubicin-loaded CA-PEI micelles as carriers for
targeted antitumor drug delivery system.
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